Qingdao NovelBeam Technology Co.,Ltd.

SHSE:688677 Stock Report

Market Cap: CN¥4.4b

Qingdao NovelBeam TechnologyLtd Valuation

Is 688677 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688677 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688677 (CN¥36.4) is trading above our estimate of fair value (CN¥23.67)

Significantly Below Fair Value: 688677 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688677?

Key metric: As 688677 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688677. This is calculated by dividing 688677's market cap by their current earnings.
What is 688677's PE Ratio?
PE Ratio35.1x
EarningsCN¥124.91m
Market CapCN¥4.39b

Price to Earnings Ratio vs Peers

How does 688677's PE Ratio compare to its peers?

The above table shows the PE ratio for 688677 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.8x
688626 Xiangyu MedicalLtd
40x36.6%CN¥4.9b
300314 Ningbo David Medical Device
41.2xn/aCN¥3.6b
300396 Dirui IndustrialLtd
19.3x40.5%CN¥4.5b
688581 HangzhouS MedTech
18.8x22.3%CN¥5.1b
688677 Qingdao NovelBeam TechnologyLtd
35.1x34.7%CN¥4.4b

Price-To-Earnings vs Peers: 688677 is expensive based on its Price-To-Earnings Ratio (35.1x) compared to the peer average (29.8x).


Price to Earnings Ratio vs Industry

How does 688677's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
688677 35.1xIndustry Avg. 35.2xNo. of Companies17PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 688677 is good value based on its Price-To-Earnings Ratio (35.1x) compared to the CN Medical Equipment industry average (35.2x).


Price to Earnings Ratio vs Fair Ratio

What is 688677's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688677 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.1x
Fair PE Ratio31.5x

Price-To-Earnings vs Fair Ratio: 688677 is expensive based on its Price-To-Earnings Ratio (35.1x) compared to the estimated Fair Price-To-Earnings Ratio (31.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688677 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥36.40
CN¥48.75
+33.9%
28.2%CN¥62.50CN¥35.00n/a2
Nov ’25CN¥38.40
CN¥48.75
+27.0%
28.2%CN¥62.50CN¥35.00n/a2
Oct ’25CN¥35.40
CN¥48.75
+37.7%
28.2%CN¥62.50CN¥35.00n/a2
Sep ’25CN¥28.68
CN¥54.25
+89.2%
15.2%CN¥62.50CN¥46.00n/a2
Aug ’25CN¥32.42
CN¥54.25
+67.3%
15.2%CN¥62.50CN¥46.00n/a2
Jul ’25CN¥39.26
CN¥54.25
+38.2%
15.2%CN¥62.50CN¥46.00n/a2
Jun ’25CN¥42.85
CN¥60.75
+41.8%
2.9%CN¥62.50CN¥59.00n/a2
Nov ’24CN¥58.03
CN¥79.66
+37.3%
18.4%CN¥94.32CN¥65.00CN¥38.402
Oct ’24CN¥57.00
CN¥92.52
+62.3%
1.9%CN¥94.32CN¥90.71CN¥35.402
Sep ’24CN¥51.50
CN¥92.52
+79.6%
1.9%CN¥94.32CN¥90.71CN¥28.682
Aug ’24CN¥50.16
CN¥92.52
+84.4%
1.9%CN¥94.32CN¥90.71CN¥32.422
Jul ’24CN¥56.74
CN¥92.52
+63.1%
1.9%CN¥94.32CN¥90.71CN¥39.262
Jun ’24CN¥65.00
CN¥101.46
+56.1%
12.6%CN¥119.35CN¥90.71CN¥42.853
May ’24CN¥69.15
CN¥106.84
+54.5%
11.7%CN¥119.35CN¥94.32CN¥44.782

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies